Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results

San Francisco, CA (March 12, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended December 31, 2014. Conference Call and Webcast at 4:30 p.m. Eastern / 1:30 p.m. Pacific KindredBio today announced its fourth quarter financial results and provided updates on its programs. Development Updates KindredBio continues to build and […]

KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 12, 2015 SAN FRANCISCO, California. (March 3, 2015) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its fourth quarter and year-end 2014 financial results […]

KindredBio Announces Update on AtoKin and Atopic Dermatitis Program

SAN FRANCISCO, California. (December 3, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs […]

KindredBio to Announce Third Quarter 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2014 SAN FRANCISCO, California. (November 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its third quarter 2014 financial results on November […]

Kindred Biosciences Announces Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis

SAN FRANCISCO, California. (Aug 20, 2014) – Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that its pivotal field study (KB010) of CereKin, an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, did not meet its primary […]